

## SUMÁRIO/CONTENTS

Mensagem de Boas-Vindas	3
Comissão Científica e Comissão Organizadora do Congresso	4
Programa Científico	6

## SESSÕES

LES: O QUE EXISTE E O FUTURO	20
• What's now, what's future in SLE treatment?	20
Doria A	
OSTEOARTROSE: NOVIDADES DA «VELHA» SENHORA	20
• Osteoarthritis – state of the art	20
Rocha FA	
• Osteoartrose ou osteoartrite?	21
Faustino A	
SÍNDROME DE SJÖGREN	21
• Síndrome de Sjögren em Portugal	21
Barcelos F	
• EULAR new guidelines	21
Barone F	
PULMÃO NAS DOENÇAS REUMÁTICAS	22
• O que fazer quando existe suspeita de envolvimento pulmonar?	22
Morais A	
• Tratamento atual do envolvimento do pulmão nas doenças reumáticas: dos AINES aos anti-fibróticos	22
Cordeiro A	
PATIENT- INOVATION / INOVAÇÃO EM REUMATOLOGIA	23
• Inovação em Reumatologia	23
Canhão H	
RHEUMA LINKS	24
Pereira da Silva JA	
PLANEAMENTO FAMILIAR E GRAVIDEZ NAS DOENÇAS REUMÁTICAS INFLAMATÓRIAS	24
• Family planning and pregnancy in inflammatory rheumatic diseases	24
Nelson-Pierecy C	

## COMUNICAÇÕES ORAIS

## GRUPO I – 2 MAIO

• CO35 – Pattern of drug use in systemic lupus erythematosus and reasons for drug discontinuation in real world clinical practice	29
• CO53 – Membranous versus proliferative lupus nephritis: two different diseases?	33

## SUMÁRIO/CONTENTS

- CO40 – ReumaHeart: cardiovascular risk in inflammatory rheumatic disease – a Portuguese population based study 31
- CO55 – Comparative long-term effectiveness of switching to another tumour necrosis factor antagonists, tocilizumab or rituximab in patients with rheumatoid arthritis and inadequate response to a first-line TNF inhibitor 24

**GRUPO II – 3 MAIO**

- CO134 – Association between memory B-cells and phenotypic features of primary Sjögrens syndrome 40
- CO200 – Efficacy and cost analysis of a systematic switch from originator infliximab to biosimilar ct-p13 of all patients with inflammatory arthritis from a single center 44
- CO198 – Drug concentrations and anti-drug antibodies analysis of a systematic switch from originator infliximab to biosimilar (CT-P13) in routine care 43
- CO93 – Retention of tocilizumab as monotherapy versus TNF inhibitors with conventional synthetic DMARDS in rheumatoid arthritis patients with inadequate response to TNF inhibitors: a study from the Tocerra collaboration 36

**GRUPO III– 4 MAIO**

- CO149 – Thirty months of Reuma.pt/Scleroderma – special focus on interstitial lung disease 41
- CO8 – Performance of referral strategies for spondyloarthritis: a population-based nationwide study 27
- CO1 – Progression of structural damage on MRI of the spine and sacroiliac joints in patients with axial spondyloarthritis is limited: the 5–year results in the DESIR cohort 26

**GRUPO IV– 5 MAIO**

- CO104 – A phase 3 randomized, placebo-controlled, double-blind study of upadacitinib (ABT-494), a selective JAK-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic dmards 38
- CO15 - Eligibility criteria for TNFi therapy in axSpA: going beyond BASDAI 28
- CO87 – Fall determinants in the adult Portuguese population 36
- CO185 – Self-reported low-energy fractures and associated risk factors in diabetic Portuguese patients: a cross-sectional population-based Study 42
- CO45 – Determinants of non-nociceptive pain in rheumatoid arthritis 32

**VISITA AOS POSTERS I (GRUPO I) – 2 MAIO**

- P12 – Inflammation on MRI of spine and sacroiliac joints is highly predictive of structural damage in axial spondyloarthritis: the 5 years data of the DESIR Cohort 53
- P4 – Which imaging outcomes for AxSpA are most sensitive to change? A 5-year analysis of the DESIR Cohort 49
- P3 – Integrated longitudinal analysis increases precision and reduces bias: a comparative 5-year analysis in the DESIR Cohort 48
- P9 – Antibody profile and systemic sclerosis clinical features – myth or reality? 50
- P11 – Nailfold capillaroscopy in systemic sclerosis – six years in review 52
- P10 – O paradigma das neuropatias periféricas nas doenças reumáticas sistémicas – dois anos em revista 51

## SUMÁRIO/CONTENTS

• P188 – RA-Voice: evaluating laryngeal involvement in Rheumatoid arthritis patients, a preliminary report	113
• P128 – Is there an effect of tocilizumab in serum autoantibodies levels in rheumatoid arthritis?	92
• P46 – The effect of certolizumab pegol on skin manifestations of psoriatic arthritis over 4 years of treatment in patients with and without prior Anti-TNF exposure	65
• P7 – Ectasia dural com multi-radiculopatia lombar: uma manifestação rara da espondilite anquilosante	144
• P47 – The efficacy of certolizumab pegol over 4 years in psoriatic arthritis patients with and without concomitant use of DMARDs	66
• P193 – Serum levels of DKK2 and sFRP1 are associated to incident fragility fractures in older women	117
• P170 – Secondary osteoporosis prevention creation of an osteoporosis outpatient clinic: report of first year experience	109
• P171 – The effect of biologic disease-modifying antirheumatic drugs in targeting disease remission in axial spondyloarthritis (axSpA): a systematic literature review	110
• P205 – Loss to follow-up in registries of rheumatic patients treated with biologics: a potentially valuable hidden real-world data that is being overlooked?	123
• P103 – Multi-Country, cross-sectional study to determine patient-specific and general beliefs toward medication and their treatment adherence to selected systemic therapies in six chronic immune-mediated inflammatory diseases (ALIGN): overall results and prelimin	83
• P150 – Resultados da utilização e satisfação com uma linha de apoio telefónico em reumatologia: experiência de 78 meses de um hospital de dia e consulta de artrite precoce	100
• P102 – Effects of Ab501 (certolizumab mice equivalent) in arthritis bone loss	82
• P119 – Work productivity among workers with axial spondyloarthritis	89
• P124 – The value of a rheumatology/radiology multidisciplinary team meeting	90
• P109 – Is the patient-acceptable status similar across 7 domains of health in patients with Rheumatoid Arthritis (RA)? Post-hoc analyses from the validation in 549 patients of the Rheumatoid Arthritis Impact of Disease (RAID) score	86
• P107 – Adaptation and validation of the rheumatoid arthritis quality of life (RAQOL) scale for Portugal	85
• P225 – Adaptação cultural e propriedades psicométricas da versão portuguesa da Global Back Recovery Scale em indivíduos com dor lombar crónica.	129

## VISITA AOS POSTERS II (GRUPO II) – 3 MAIO

• P27 – Multifactorial explanatory model of depression in patients with rheumatoid arthritis: a structural equation approach	60
• P29 – Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modeling approach	61
• P201 – Tumor necrosis factor inhibitors persistence in psoriatic arthritis patients	120
• P69 – Certolizumab pegol mice equivalent reduces inflammation and bone damage in tmTNF transgenic mice	75
• P96 – The social pattern of sarcopenia in Portugal	79
• P157 – Fiabilidade e validade de Constructo do questionário PainDETECT	105
• P230 – Biossimilares: a perspectiva de reumatologistas portugueses	131
• P125 – Tools for the screening of sarcopenia: a head-to-head comparison by the NOVA SarcoAging Group	91
• P97 – The temporal pattern of sarcopenia in 22 European countries	79

## SUMÁRIO/CONTENTS

• P19 – Renal and overall survival analysis in a cohort of patients with lupus nephritis with up to 40 years of follow up	55
• P25 – Physician awareness of rheumatic immune-related adverse events in cancer patients treated with immune checkpoint inhibitors	58
• P105 – Follicular CD8 T cells: correlation with circulating B cells and disease activity in primary Sjögren's Syndrome	84
• P33 – Septic Arthritis: a reality of a Portuguese department of rheumatology	62
• P159 – Fragility hip fracture after the age of 90 – the experience of a fracture liaison service	105
• P176 – Contraceptive counseling and use among portuguese women with systemic lupus erythematosus	112
• P172 – Factors predicting difficulties with discharge to own home in patients with fragility hip fractures	111
• P48 – Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database	67
• P115 – Evaluation of the impact of a summer camp in children with juvenile idiopathic arthritis	88
• P199 – Densitometria óssea – a importância da medição bilateral no fémur proximal para a avaliação seriada da densidade mineral óssea	118
• P168 – «Espelho meu, espelho meu...» – percepção da imagem corporal nos doentes com artrite reumatóide	108
• P169 – Adesão terapêutica, autoestima e afeto em doentes com artrite reumatóide	108
• P216 – O afeto positivo como variável preditora da adesão terapêutica em doentes com artrite reumatóide	126
• P219 – O papel da ecografia articular no diagnóstico de gota	127
• P86 – Efficacy of 5-year therapy with mycophenolate mofetil in systemic lupus erythematosus	76
• P88 – The effect of biologic disease-modifying antirheumatic drugs in radiographic progression in axial spondyloarthritis (AxSpA): a systematic literature review.	76
• P255 – Vacinas em doentes com Artrite Reumatóide – a realidade de duas unidades de saúde familiar	139
• P253 – Referenciação à consulta de reumatologia – a realidade de uma unidade de saúde familiar	138
• P156 – Does disease activity affect the B-cell compartment in ankylosing spondylitis?	104
• P164 – Sacroiliac joint MRI and the contribution of Rheumatology/Radiology multidisciplinary team meetings	106
• P212 – Do ASAS, ASDAS and BASDAI therapy response evaluation translate the same information?	124
• P173 – Estudo misto sobre um programa de fisioterapia em grupo baseado no exercício e educação para utentes com fibromialgia	112
• P248 – Switching to biosimilars: what have we learned?	135
• P194 – Processo assistencial integrado do adulto com osteoporose no serviço de reumatologia e doenças ósseas metabólicas do Hospital de Santa Maria – CHLN	118
• P191 – Caracterização dos doentes com artrite idiopática juvenil seguidos na consulta de reumatologia pediátrica do Centro Hospitalar Universitário do Algarve	115
• P133 – Terapêutica biológica e gravidez em mulheres com doença reumática inflamatória sistémica: resultados preliminares de uma coorte portuguesa	93
• P153 – Premature ovarian failure in premenopausal women with systemic lupus erythematosus and systemic vasculitis treated with intravenous cyclophosphamide	101
• P23 – Early versus late-onset systemic sclerosis: are there clinical and immunological differences?	56
• P24 – Systemic Sclerosis: gender-associated differences in clinical and serological features	57
• P217 – Do symptoms of depression and anxiety influence treatment response and long-term physical health outcomes in ankylosing spondylitis?	127

## SUMÁRIO/CONTENTS

• P250 – Adherence to biologic therapy: is there any difference between spondyloarthritis and rheumatoid arthritis patients?	137
• P61 – A avaliação do nível de satisfação dos utentes de um Serviço de Reumatologia – utilização do questionário PSQ-18	70
• P214 – Patients' perspective on the efficacy and risks of glucocorticoids in RA – an initiative under the GLORIA project	125
• P247 – Health professionals' perspective on benefits and risks of low dose glucocorticoids in RA – an initiative under the GLORIA project	134
• P249 – Assessing the quality of biologic switch decisions in psoriatic arthritis: result from a modified-Delphi Consensus.	136

## VISITA AOS POSTERS III (GRUPO III) – 4 MAIO

• CC209 – Tuberculous arthritis: keeping a high index of suspicion	177
• CC18 – Esclerose sistémica e artrite psoriática: uma sobreposição rara	180
• CC210 – Macrophage activation syndrome in systemic juvenile idiopathic arthritis	177
• CC213 – Displasia fibrosa óssea: relato de 3 casos clínicos	179
• CC203 – Amiloidose renal como complicação de artrite psoriática	175
• CC187 – Dermatomyositis – when symptoms come too late	172
• CC186 – Reactive arthritis – a case to remember	171
• CC160 – Corticosteroid-induced osteoporosis for bowel inflammatory disease: a case report	168
• CC232 – Trigeminal ganglionopathy – case report of a patient with lupus and secondary antiphospholipid syndrome	183
• CC181 – Miopatia inflamatória em doente com artrite reumatóide sob adalimumab	170
• CC182 – Raquitismo hipofosfatémico – complicações frequentes de uma doença rara	171
• CC132 – Charcot Neuroarthropathy secondary to familial amyloid polyneuropathy	162
• P65 – Anti- <i>saccharomyces cerevisiae</i> antibodies in spondylarthropathies: prevalence and associations with disease phenotype	74
• P63 – Paradoxical articular effects of biological therapy in inflammatory bowel disease: experience of an hospital centre	72
• P204 – Vasculite crioglobulinémica: revisão de casos nos últimos 15 anos num serviço de reumatologia	122
• P34 – Maternal weight gain during pregnancy and offspring bone mass: different associations in healthy weight versus overweight women	62
• P220 – Changing patterns of multimorbidity in the general population: the contribution of osteoarthritis	128
• P137 – Knowledge, confidence and educational needs of primary care nurses on patient education and continuity care in rheumatic diseases	94
• P37 – Celastrol controls inflammation by decreasing human blood cellular activation in vitro	63
• P151 – Extended oligoarticular and polyarticular juvenile idiopathic arthritis patients have a similar B cell phenotype when compared to established rheumatoid arthritis	101
• P228 – Bone disease in a Cystic Fibrosis cohort – a descriptive analyses	130
• P62 – The effect of biologic disease-modifying antirheumatic drugs patient reported outcomes in patients with axial spondyloarthritis: a systematic literature review and a call for action	71
• P64 – Lumbar multifidus myofascial mechanical physical properties in healthy adults using different devices	73

## SUMÁRIO/CONTENTS

• CC60 – Tocilizumab: uma alternativa terapêutica para a vasculite primária do SNC?	149
• CC49 – Doença de Kikuchi-Fujimoto associada a doença mista do tecido conjuntivo: um caso de recidiva	147
• CC81 – Belimumab no tratamento do lúpus eritematoso sistémico: a experiência de um centro	155
• CC72 – Artrite séptica complicada com abscessos da parede torácica e osteomielite do manúbrio – relato de um caso	152
• CC207 – Mal de Pott – relato de um caso	176
• CC122 – Systemic sclerosis developing in association with pegylated interferon-alpha	161
• CC211 – Sinovite de corpo estranho a pico de palmeira – um caso de biópsia sinovial diagnóstica e terapêutica	178
• CC152 – Basalioma e anti TNF alfa: revisão a propósito de um caso clínico	168
• CC257 – Insuficiência cardíaca congestiva, um saco para muitas doenças – a propósito de um caso clínico	184
• CC138 – Esclerose sistémica e miosite como doença paraneoplásica: associação a mieloma múltiplo	163
• CC56 – Osteoartropatia hipertrófica apenas a ponta do iceberg	148
• P154 – Neoplasms in patients with systemic sclerosis: a retrospective study of a center	102
• P155 – Eficácia da terapêutica com tocilizumab em monoterapia versus em associação com csDMARDs: real-world data	103
• P99 – A fragile bridge: an evaluation of primary care referral letters to rheumatology consultation	81
• P143 – Rheumatology electives: evaluation of 87 residents – what quality means?	95
• P144 – Integrated care process for systemic lupus erythematosus: towards quality in healthcare	96
• P50 – Síndrome de Erasmus: raro ou subdiagnosticado?	68
• P51 – Síndrome de Erasmus e esclerose sistémica sem exposição à sílica: manifestações clínicas diferentes?	69
• P147 – Obesidade e artrite reumatóide: influência na atividade da doença e na qualidade de vida	97
• P26 – Somatosensory dysfunction in Rheumatoid arthritis – a quantitative sensory testing assessment	59
• P44 – Is the radiographic damage a risk factor for neuropathic pain in Rheumatoid Arthritis patients?	65
• P43 – Predictors of fragility fractures and bone mineral density variation in a Spondyloarthritis cohort	64
• P98 – Clinical outcomes of the first 100 patients evaluated at a multidisciplinary Sjögren's Syndrome clinic	80

---

 VISITA AOS POSTERS IV (GRUPO IV) – 5 MAIO
 

---

• CC140 – Era apenas uma epistáxis: um caso clínico de doença de Rendu-Osler-Weber	165
• CC76 – Flare de artrite reumatóide após artroplastia total do joelho: relato de um caso	153
• CC85 – Miopatia por corpos de inclusão e seu tratamento: relato de um caso clínico	157
• CC22 – Cogans syndrome: a rare systemic vasculitis	145
• CC224 – Consulta multidisciplinar reumatologia/imagiologia: série de casos com alteração diagnóstica relevante	181
• CC227 – Sintomatologia músculo-esquelética associada às infeções HCV – série de casos	182
• CC41 – Central nervous system vasculitis as primary manifestation of systemic lupus erythematosus in a patient with cutaneous lupus erythematosus	146
• CC161 – Visceral leishmaniasis versus systemic lupus erythematosus flare-old axioms sometimes stay true other times not	169

## SUMÁRIO/CONTENTS

• CC112 – High sedimentation rate doesn't always mean giant cell arteritis	160
• P21 – Artrite reumatóide VS polimialgia reumática – comparação das alterações ecográficas em doentes com omalgia bilateral de novo	56
• CC121 – Risco cardiovascular em artrite reumatóide, a propósito de um caso clínico	160
• CC82 – Artrite da articulação temporomandibular: a manifestação inicial de espondilite anquilosante?	156
• CC136 – Uveíte mascarada	163
• CC146 – Nevrite óptica isquémica anterior – quando a clínica e o laboratório são enganadores	167
• CC66 – Silent acute myocarditis in eosinophilic granulomatosis with polyangiitis	150
• CC80 – SLE presenting with myocarditis – a case report	154
• CC71 – Síndrome hemofagocítica no lúpus eritematoso sistémico: desafio ao limite	151
• CC196 – Síndrome demencial e cegueira	174
• CC195 – Is this really refractory rheumatoid arthritis?	173
• CC215 – Um caso de arterite de células gigantes sem elevação de velocidade de sedimentação eritrocitária?	180
• CC229 – Artrite séptica sem subida de parâmetros inflamatórios: um caso em doente reumático sob imunossupressão	183
• CC79 – Cutaneous and peripheral nervous system vasculitis – a presenting manifestation of SLE/Sjögren overlap	153
• CC108 – Sarcoidose e doença de Still do Adulto, uma associação invulgar?	158
• CC110 – Neuro-Behçet como manifestação inaugural da doença a propósito de um caso clínico	159
• CC139 – Iatrogenic Kaposi sarcoma in giant cell arteritis – a clinical case	164
• CC142 – Old thalidomide remains an option for refractory cutaneous lupus erythematosus	166
• CC42 – Artrite psoriásica PMR-like: novo fenótipo?	146
• CC197 – Tratamento biológico em doente com LES refratário à terapêutica convencional	174
• P256 – Avaliação do consumo de AINES em doentes com artrite reumatóide e espondilite anquilosante no controlo da dor – retrato de uma unidade de reumatologia	140
• P237 – Rastreio e tratamento de tuberculose latente num centro hospitalar de Lisboa – intervenção na consulta de risco de infeção na imunomodulação	133
• P106 – Long-Term safety of adalimumab (HUMIRA) in adult patients from global clinical trials across multiple indications: an updated analysis in 29,987 patients representing 56,951 patient-years	85
• P148 – Achados ecográficos em doentes com gota.	99
• P95 – Individual responder analysis of the effectiveness of manual therapy and exercise versus usual care in patients with chronic nonspecific neck pain: preliminary results of a randomized controlled trial	78
• P236 – Remission rates of biologic-treated rheumatoid arthritis, spondyloarthritis and psoriatic arthritis patients: a single-center cross-sectional study	132
• P111 – Effectiveness of Tocilizumab (TCZ) among rheumatoid arthritis patients: first-line versus subsequent users	87
• P190 – Poor response to hepatitis B vaccination in rheumatic patients treated with biologic therapy – preliminary results of an observational study	114
• P192 – Tocilizumab abrogates expansion of activated Tfh cells following influenza vaccination and partially limits vaccine response in rheumatoid arthritis patients	116